French drugmaker Sanofi announced on Tuesday a collaboration with artificial intelligence company OpenAI and Formation Bio to enhance its drug development projects using AI technology.
Sanofi stated that the partnership with OpenAI will grant it access to proprietary data for developing AI models tailored to its biopharma initiatives, while Formation Bio will contribute additional engineering expertise.
Major pharmaceutical companies are increasingly leveraging artificial intelligence to quickly identify suitable patients for clinical trials and to minimize the number of participants required for testing new medicines. This approach accelerates drug development and can potentially save millions of dollars.